13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839435
Total reported value
$1.1B
$1.1B
29 檔
39.3%
As reported in its official Q1 2026 Form 13F filing, Octagon Capital Advisors LP's tracked investment portfolio stood at $1.1B with 29 total positions.
Octagon Capital Advisors LP executed strategic sector rebalancing during Q1 2026, establishing 8 new positions while fully exiting 6 holdings and trimming 9 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 18.08% | -1.94% | -19.45% | |
| 2 | COGT | Cogent Biosciences Inc | Stock-Other | 10.01% | -1.84% | — | |
| 3 | ABVX | Abivax Sa-adr | Stock-Other | 8.34% | +3.55% | -10.45% | |
| 4 | ALMS | Alumis Inc | Stock-Other | 6.90% | +0.26% | +11.85% | |
| 5 | DFTX | Definium Therapeutics Inc | Stock-Other | 5.10% | +7.37% | — | |
| 6 | AVBP | Arrivent Biopharma Inc | Stock-Other | 5.03% | +1.12% | — | |
| 7 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 4.38% | +1.55% | — | |
| 8 | KYMR | Kymera Therapeutics Inc | Stock-Other | 3.92% | -0.72% | -20.56% | |
| 9 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 3.46% | +0.11% | — | |
| 10 | BIOA | Bioage Labs Inc | Stock-Other | 3.38% | +0.47% | +9.39% | |
| 11 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.30% | -3.30% | EXIT | |
| 12 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.23% | -3.23% | EXIT | |
| 13 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.15% | -0.49% | — | |
| 14 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 3.09% | -3.09% | EXIT | |
| 15 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.97% | -1.14% | +20.70% | |
| 16 | PALI | Palisade Bio Inc | Stock-Other | 1.99% | -0.06% | +7.40% | |
| 17 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.96% | -1.43% | -47.25% | |
| 18 | IRON | Disc Medicine Inc | Stock-Other | 1.91% | -0.13% | — | |
| 19 | AKTS | Aktis Oncology Inc | Stock-Other | 1.90% | +0.88% | — | |
| 20 | CNTX | Context Therapeutics Inc | Stock-Other | 1.52% | -1.37% | — | |
| 21 | DTIL | Precision Biosciences Inc | Stock-Other | 1.36% | -0.41% | +16.62% | |
| 22 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 1.33% | -0.48% | — | |
| 23 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 0.73% | -0.31% | — | |
| 24 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.71% | -0.71% | EXIT | |
| 25 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.70% | -0.70% | EXIT | |
| 26 | PHVS | Pharvaris N.V. | Stock-Other | 0.52% | +0.90% | -75.43% | |
| 27 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.37% | -0.37% | EXIT | |
| 28 | EVMN | Evommune Inc | Stock-Other | 0.37% | -0.36% | EXIT | |
| 29 | GOSS | Gossamer Bio Inc | Stock-Other | 0.28% | -0.17% | -44.31% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics Inc | +6% | -19.45% | Trim |
| 2 | ALMS | Alumis Inc | +3.9% | +11.85% | Add |
| 3 | 260 | Centessa Pharmaceuticals-adr | +1% | — | Unchanged |
| 4 | BIOA | Bioage Labs Inc | +0.8% | +9.39% | Add |
| 5 | 4XC1 | Kalvista Pharmaceuticals Inc | +0.7% | +13.87% | Add |
| 6 | DTIL | Precision Biosciences Inc | +0.4% | +16.62% | Add |
| 7 | AVBP | Arrivent Biopharma Inc | +0.2% | — | Unchanged |
| 8 | UNCY | Unicycive Therapeutics Inc | 0% | — | Unchanged |
| 9 | DBVT | Dbv Technologies Sa-spon Adr | 0% | — | Unchanged |
| 10 | COGT | Cogent Biosciences Inc | -0.1% | — | Unchanged |
| 11 | EVMN | Evommune Inc | -0.7% | -71.31% | Trim |
| 12 | PALI | Palisade Bio Inc | -0.7% | +7.40% | Add |
| 13 | BBOT | Bridgebio Oncology Therapeut | -0.9% | -31.07% | Trim |
| 14 | OCUL | Ocular Therapeutix Inc | -0.9% | +20.70% | Add |
| 15 | KYMR | Kymera Therapeutics Inc | -1.1% | -20.56% | Trim |
| 16 | LXEO | Lexeo Therapeutics Inc | -1.4% | -36.23% | Trim |
| 17 | TSHA | Taysha Gene Therapies Inc | -1.5% | — | Unchanged |
| 18 | PHVS | Pharvaris N.V. | -1.7% | -75.43% | Trim |
| 19 | TRVI | Trevi Therapeutics Inc | -2.3% | -47.25% | Trim |
| 20 | ABVX | Abivax Sa-adr | -4% | -10.45% | Trim |
| 21 | GOSS | Gossamer Bio Inc | -5% | -44.31% | Trim |
| 22 | DFTX | Definium Therapeutics Inc | — | NEW | New buy |
| 23 | MIRM | Mirum Pharmaceuticals Inc | — | NEW | New buy |
| 24 | BRD1EUR | Mind Medicine Mindmed Inc | — | EXIT | Sold out |
| 25 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 26 | 430 | Terns Pharmaceuticals Inc | — | NEW | New buy |
| 27 | CGON | Cg Oncology Inc | — | EXIT | Sold out |
| 28 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 29 | RAPT | Rapt Therapeutics Inc | — | EXIT | Sold out |
| 30 | IRON | Disc Medicine Inc | — | NEW | New buy |
| 31 | AKTS | Aktis Oncology Inc | — | NEW | New buy |
| 32 | CNTX | Context Therapeutics Inc | — | NEW | New buy |
| 33 | CRBP | Corbus Pharmaceuticals Holdi | — | EXIT | Sold out |
| 34 | PEPG | Pepgen Inc | — | EXIT | Sold out |
| 35 | CATX | Perspective Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Octagon Capital Advisors LP reported a total U.S. public equity portfolio value of $1.1B across 29 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DNTH, COGT, ABVX) accounted for 39.3% of total reported equity market value during Q1 2026.
Top New Position Initiated
DFTX
市值: $46.1M
Top Position Liquidated / Trimmed
BRD1EUR
前期市值: $29.9M
During Q1 2026, Octagon Capital Advisors LP's top holdings by market value included DNTH (18.1%)、COGT (10.0%)、ABVX (8.3%). The largest single position, DNTH, represented 18.1% of total portfolio value.
In Q1 2026, Octagon Capital Advisors LP made 29 total portfolio adjustments, initiating 8 new buys, adding to 6 positions, trimming 9 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.